Dr. Clove is here to answer that question.

Anyone who lives long enough will stumble upon a disease - cataracts - at some point in their lives.

In China, the prevalence rate for people over 60 years old is 65%.If left unchecked, the result can be blindness - cataract tops the list of causes of blindness in China, at 47%.

Ophthalmologists often joke that if anyone can develop a drug to treat cataracts, they will have no problem winning a Nobel Prize.

The vast majority of the world doesn't have a drug like this, but China does, and it sells hundreds of millions of yuan every year, and you must have heard of it-Sapolex (brand name)。

Image source: Sapience official website

Want to know how brainwashing it is? Do an online search for "Sapiens cartoon image commercials" and open the video to watch it:

Image: Screenshot from the video of the Sapphire cartoon image campaign

One,Brainwashing Chinese miracle drugs

How divine is the 'miracle drug' that you see on the screen? Just look at the elders and friends around you who are tirelessly buying them.This 'miracle drug' sold 28 million units in 2016 alone, with annual sales of 750 million RMB.

In commercials, it's pretty much everything:

▼ In the old ads, almost all eye problems could be dropped

▼ If you have cataracts, use Saproxil.

It's too late to wait until you go blind! Sticking to the drops is the key!

Image credit: Screenshot of an old Saphris advertisement

▼ Cataracts, Difficulty Seeing, Saphris Drops for Eyes ...... has become a popular segment on social media

Image credit: Saproxil's latest advertisement

▼ It causes blindness. Are you afraid? We can cure it!

Image credit: Sapience Taobao Ads

In 2016 alone, Saproxis spent a whopping RMB 260 million on advertising, while the same year's drug R&D expenses were only $29 million, and only $5.5 million for cataract-related drugs, not even a fraction of the advertising costs.

Image credit: Sapiens 2016 company financial report

With the support of huge advertising costs, Saphris Eye Drops take turns brainwashing with various advertisements, literally taking out the old, the middle-aged, the young and the young, all in one go!

It's the first thing people think of whenever their eyes are uncomfortable.

Image Source: Web Screenshot

Second, the miracle drug hated by ophthalmologists

Suffice it to say, Sapphire has almost fulfilled the dream of nearly 40,000 ophthalmologists across the country - toTo make the people aware of the need and urgency of cataract prevention and treatment.

However, this seemingly 'conscientious' drug is not supported by ophthalmologists.

On the contrary, it is a drug that is extremely hated by ophthalmologists!

Image source: some eye disease science article messages

When Saproxel went public in 1997, it was promoted primarily in hospitals, and Saproxel's prospectus noted that "the company did not achieve the expected results despite its best efforts to promote the company in hospitals."

Obviously, ophthalmologists aren't very good at fooling around, but the same can't be said for the general public.

In 2004, the State Drug Administration approved the conversion of Saphris Ophthalmic Solution to an OTC drug.

This meant that it could be taken out of the constraints of ophthalmologists and directed to the general public, which led to the series of magical brainwashing advertisements at the beginning of the article that started the road to Saproxil's money-sucking success.

III. Fake science, real marketing

The miracle drug destroys the public's perception

Some pharmaceutical companies invent new drugs that change the course of mankind's fight against diseases and earn their own profits as well.

There are also pharmaceutical companies that destroy the public's proper perception of disease for the sake of high profits.

Currently, it is the consensus of ophthalmologists worldwide that the only effective treatment for cataracts is surgery.

The 8th edition of Ophthalmology states that there are more than 10 types of anti-cataract medications in clinical use, including traditional Chinese medicines, but their efficacy is not very precise.

Surgery is the most effective way to treat cataracts, regardless of the type of cataract, says the China Prevention of Blindness and Treatment of Blindness Network, an organization of the National Health and Planning Commission (NHPC). So far, no drug has been proven to cure cataracts or stop their progression.

The American Academy of Ophthalmology's 2016 Clinical Guidelines for Cataracts in Adults states that, in humans, no single medication has been found to be effective in treating or slowing the progression of cataracts. Ophthalmologists should make this clear to their patients.

Many ophthalmologists have told us that many elderly people, when they hear that they have to go to the hospital and undergo an operation, will have a heart attack, and Saproxis has taken advantage of such a mentality.

We interviewed several doctors to give us the true psychology of the patients they encountered.

Hongping Cui is the director of ophthalmology at Oriental Hospital and the first ophthalmologist to point out the dangers of Saproxil marketing:

"Saproxis is precisely taking advantage of human's fear of surgery to wrongly publicize that cataracts can be cured without surgery, and my specialist clinic encounters this kind of patients every week. If it really cures cataracts, it will have no problem winning the Nobel Prize."

Professor Li Can, chief ophthalmologist of the First Hospital of Chongqing Medical University, gave us an analysis of the psychology of the elderly:

90% of the patients who come to our clinic have used Saproxel, but almost all of them decide to come for surgery after using it, and they are willing to give it a try if they can stop their cataracts by buying a little medicine". Elderly people are generally stubborn, they don't trust doctors, they trust people they trust on TV, and they trust the words of the "experts" on the Health Channel."

Prof. Yi Lu from the Department of Ophthalmology, Ear, Nose and Throat of Fudan University has also come across many such patients:

"Most of the patients we encounter in the clinic are patients who have had eye drops and still end up coming in for surgery, and from an ophthalmologist's point of view, it's clear that the drug doesn't work," he said.

Yes, if you have eye problems, you can just take a few drops of eye drops and you'll be fine, how convenient.

Some old people, under the publicity of advertisements, take a drop for half a year, a year, or even several years, and they are not willing to go for surgery even though their eyesight is getting worse and worse, firmly believing that the eye drops can cure him. However, in reality, if surgery is not performed, the result will probably still be blindness.

Prof. Cui Hongping said that he has come across many patients who drop eye drops until their cataracts are overripe, leading to glaucoma and uveitis. A problem that could have been solved with a ten-minute surgery, leaving the patient delayed for years and in a blur, not only sacrificing quality of life for a long period of time, but also increasing the risk of surgery when it eventually becomes unavoidable.

Image credit: Screenshot of Dr. Cui Hongping's Weibo account

A disease that could have been cured with a minor surgery in the hospital, but because of these eye drops, the old man has been living in a blurry world for half a year, a year, years ......

They can't see the TV, the furniture in their homes, the food on the table, whether there are cars on the road, or even what their grandchildren look like ......

But really, they could have had a clear, happy life.

What is even more frightening is that when cataracts are not serious, surgery is relatively simple; however, if you insist on eye drops and delay surgical treatment until you have overripe cataracts, it will increase the difficulty of the surgery, which will not only cost you more money, but may also affect the recovery of your vision after the surgery. Some patients may also experience serious complications such as glaucoma and uveitis.

All of this, the Saphris ads don't tell you.

On the official website of Saphris, there is this statement:

Corporate vision: As long as they are middle-aged or elderly, they must use Saphris.

Fourth, do foreign countries use miracle drugs?

If the lens of the eye is compared to an egg, as time slowly passes and age increases, the protein inside the eye gradually denatures, just like an egg being cooked a little bit, and this process is irreversible.

The only thing that works at the moment: change the egg (surgery).

But that's not how Saproxel sees it. In the prospectus of this publicly traded company, it says that in the early stages of cataract disease, medications are the mainstay of clinical treatment for early-onset senile cataracts.

It's written in the bare bones of the Sapphire propaganda:

Image source: Sapience official website

Preventive treatment of cataracts, recognizing Saproxil?

The active ingredient in Saphris Eye Drops is called Bendazac Lysine, which has been shown to be effective in delaying cataracts in a few animal studies.

But when it comes to the human body, there is no drug in the world that has been proven to be effective in preventing or treating cataracts, not Saproxil (Bendazac Lysine), nor any other drops, wipes, or pills. The only definitive and effective treatment is surgery.

We asked several of the country's top ophthalmologists about the treatment of cataracts in various countries.

Prof. Lu Yi from the Department of Eye, Ear, Nose and Throat of Fudan University told us this:

"Drug treatment of cataracts is a Chinese specialty, and drug treatment is almost rare abroad, where cataracts are either surgically treated or, in the early stages, some patients may be able to temporarily improve their vision by wearing glasses.

This is because these drugs are effective in animal studies, but there are no human trials to confirm their therapeutic effect on cataracts in humans.

Honestly, this thing is too much of a flop. No country has a market for cataract treatment drugs as big as China's."

Dr. Cui Hongping made a graphic analogy:

"The pharmacological effects of many drugs are theoretical, and their actual use in humans may be a different matter. If drugs that are effective in animal experiments could be used in humans, cancer would have been cured a long time ago.

There are also very few medications for cataracts abroad; they are prescription medications, and doctors usually tell their patients that they are essentially ineffective. Why are such drugs still available? Very often it is a placebo, some people it because of physical reasons or because of personal mental problems really can not accept the operation, and then give him some medicine as a placebo.

When ophthalmology conferences are held every year around the world, from the United States to Europe to China there is a consensus that so far there is no drug that can treat cataracts."

Saproxel's great commercial success was due to the fact that it received marketing authorization in the 1990s, when China's drug regulatory system was not as strict about clinical trials for drugs, and there was no established mechanism for delisting drugs in China.

Dr. Choi also made a suggestion:

"Since so many ophthalmologists to question this matter, the State Drug Administration is not able to require him to re-conduct rigorous large-scale clinical trials, you are already a publicly traded company, making billions of dollars, take out two hundred million to do a clinical trial, to give everyone an explanation, this requirement is not too much, right."

Taking a step back, the approved indication for Saphris is 'early age-related cataracts', yet the company blurred out the word early in its brainwashing advertisements long ago.

Image credit: Screenshot of Saproxil advertisement

Saphris not only advertises that it can prevent and treat cataracts, it also lists the symptoms of cataracts.This is the smartest part of the ad: replacing the disease with a symptom.

What are you talking about? Have you been diagnosed?

Cataracts do have symptoms such as dark shadows and double vision, but many eye diseases do!

This can lead to many, many more 'patients'. Many people run to the drugstore, online, or even in the hospital to buy Saproxil drops for their eyes because they have watched the advertisements, listened to the propaganda, and realized that they have the same symptoms, and their doctors can't even stop them.

Image credit: Message from a user of one of Saproxis' online sales platforms

And the consequences of messing around with eye drops can be very serious:

• Eye drops contain preservatives that can damage the cornea when used consistently over time;

• Some people don't have cataracts at all, and they also put on random drops, delaying treatment.

For example, some glaucoma patients, do not go to the proper treatment of the disease, their own messy drops of eye drops, drops, glaucoma is getting worse and worse, may develop to the end of blindness.

Fifth, make more money by doing more brainwashing ads!

In fact, as early as 2013, Dr. Cui Hongping, director of ophthalmology at Dongfang Hospital affiliated with Tongji University, broke the news with his real name, pointing out that Saproxis had false propaganda. This claim has been supported by many ophthalmologists, and various industrial and commercial regulators have also cracked down on its illegal publicity.

Image source: Screenshot from a 2013 report

However, amidst report after report, amidst the outcry of ophthalmologists at large, instead of stopping production and going to larger scale trials, Saphris eye drops have changed their advertisements from generation to generation, gaining more and more influence, increasing their sales, and making a lot of money.

It even managed to get listed on China's A-share market in 2014, with record sales year after year.

Image source: a financial software

From 500 million in 2012, in just four years, Saproxis has created the myth of nearly 1 billion RMB in revenue, including 750 million in sales of Saproxis eye drops.

What's even scarier is that Saphris has brought new ideas to drug marketing and has become a classic case study and a model to follow.

Image Source: Web Screenshot

In the future, I wonder how many drugs, will learn from Saproxil and go on the road to marketing 'success' ......

Are your family members, relatives or friends, using Saphris drops in their eyes?

Please let more people, know the truth behind the disease and advertising and marketing.

Part of the content provided by the ophthalmologist Chia Jian, source public number Dabai clinic "Dabai have something to say, the sacred drug brush screen can be rested!

Refer to the article:

Olson R J, Braga-Mele R, Chen S H, et al. Cataract in the Adult Eye Preferred Practice Pattern®[J]. Ophthalmology, 2017, 124(2): P1-P119.

Zhao Kanshing, Yang Peizeng, Ophthalmology [M]. 8 edition, Beijing: People's Health Publishing House, 2013

World Health Organization (WHO) Fact Sheet on Visual Impairment and Blindness, http://www.who.int/mediacentre/factsheets/fs282/zh/

China Prevention and Treatment of Blindness http://www.moheyes.com/

Abdelkader H, Alany R G, Pierscionek B. Age‐related cataract and drug therapy: opportunities and challenges for topical antioxidant delivery to the lens[J]. Journal of Pharmacy and Pharmacology, 2015, 67(4): 537-550.

Balfour J A, Clissold S P. Bendazac lysine[J]. Drugs, 1990, 39(4): 575-596.

In 2012, my father's cataract symptoms appeared, and then watched the advertisement of Saproxil and thought that he could use Saproxil without surgery first. Because the advertisement was made by Mr. Lang, who was the absolute idol of my father's generation, he was convinced by the advertisement! After I used it for a while, I realized that it didn't have any effect, so I didn't continue to use it. At that time, I consulted some internal medical literature and found that Saproxil should not be too effective. Later on, I also asked my ophthalmology classmates for advice, and their opinion was that it was not very useful.

In fact, the main ingredient in the drug SaphrisIt's 'Bendazac Lysine', and the information mentions thatThis substance can inhibit the cataract formation process in theA certain enzyme that plays an important role in (aldose also(proenzyme) activity to stop the lens from becoming cloudy, theThis can play a role in slowing down the progression of cataractsUse. However, while aspirations are great, the reality is veryBoneheaded, because so far, worldwide drug therapyThere is no clear evidence-based medicine for cataracts. So at this point there is only a possible role. Here's something to remember.It is only possible that there is a role for cataracts, not that there is a definite therapeutic effect! In fact, only cataract surgery is sufficiently evidence-based regarding cataracts!The medical evidence for treatments, the therapeutic effects of any drug or nutritional supplement are not yet clear.

In fact, in addition to Saproxil being such a hotOutside of miracle drugs, there are many other kinds on the marketMedications for cataracts, such as pinoxin sodiumEye drops (intravitreal stop), pinoxin eye dropsLiquid (Kalinuyu), Musk Pearl Eye Drops,Amiodarone Eye Drops, Liming Eye Drops, etc...In addition to topical medications there are also some proprietary Chinese medicines such as FuziMing Ming Tablets, Jinhua Mingmu Pills, etc., which are mentioned in the instruction manual.to the point where it can be used in patients with early cataracts. However.Even when used as directed, these drugs are onlymay only slow cataract progression, delay cataractcataract surgery without achieving a cure for cataractsPurpose! Why? Everyone canThink about it, once a crystal becomes cloudy, it's as if theBoiled egg whites (denatured proteins), how do youWhat about the possibility of reversal? If it can't be reversed, then the selfBut it's not going to solve the underlying problem, and surgery.That is, the clouded lens is replaced with aThe treatment of a clear, transparent IOL.It's the only thing that really makes you "see the light"!

I also read the relevant literature to get a little shallow ophthalmic knowledge, I hope that some ophthalmologists come out to popularize it, so that we can understand the truth! For more health information, please follow Dr. Zhang Zhiying's headline number.

The advertisement of Saproxis for cataracts is familiar, but I never believe in advertisements. 15 years ago, I just retired and found that my vision in my left eye was decreasing greatly, and my vision was blurred when I looked far and near, so I immediately went to the ophthalmology department of the county hospital for examination, and it was confirmed that I had cataracts. A month after the surgery (surgery as long as ten minutes), 3 days out of the hospital, the effect is very good, vision is back to normal. So the elderly (the possibility of cataracts in the elderly is very large) found that vision changes (especially see far and near are blurred), must promptly go to check whether the cataracts or glaucoma, do not point out what eye drops according to their own ads, spend a small amount of money, delayed surgery is a big matter of expiration date.

December 2, "Dr. Ding Xiang" public number released "a year wildly sold 750 million brainwashing drug, please spare the elderly in China" article broke the circle of friends, I thought, Saproxis stock I'm afraid to come to a few stops, with curiosity concern Saproxis stock, Saproxis December 1, the closing price of 23.70 Sharp Ace's closing price on December 1 was 23.70, down only 3.33% on December 4, and the closing price before the suspension on December 6 was 22.10 yuan, only 6.75% higher than the closing price on December 1," he said. During the period, the general market fell, many stocks fell worse than Saproxis.

Why is this? Could there be a turnaround? See the author's analysis?

The article "Brainwashing Drugs That Sell 750 Million a Year, Please Spare China's Elderly" cites the China Prevention of Blindness and Treatment of Blindness Network under the National Health Planning Commission, the American Academy of Ophthalmology's 2016 Clinical Guidelines for Cataracts in Adults, as well as ophthalmologists: there is no medication found to be effective in treating or delaying the progression of cataracts. Seriously, it's a lie that medications are effective in treating or curing cataracts, and everyone knows it. So does Saphris slow the progression of cataracts? It's not for the experts to say, or for the Saphris company to say, it's for the clinical data to say live.

After the "Dr. Ding Xiang" article issued, Saproxis company also issued an article in the public number to respond to the question: the article mentioned that Saproxis has been through a number of hospitals Phase II, III clinical trials, showing that the total effective rate of more than 70%, and sunshine test units and personnel of the stamped documents.

For the people, what they want to know more is whether there is sufficient clinical data on the efficacy of the drug and the authenticity of the data. In the author's opinion, a responsible company should put part of its profits in clinical trials and use data to tell people whether the drug is effective or not, instead of spending hundreds of millions of dollars on advertisements (excessive marketing).

The chemical name of Saphris is Bendazac Lysine, an aldose reductase inhibitor, which inhibits the activity of aldose reductase in the eye and prevents the production of sorbitol, which can slow down the development of lens clouding. The instructions state that it is only suitable for early senile cataracts, and does not indicate indications for advanced cataracts, therefore, I believe that it should not be used for advanced cataracts and should be done as soon as possible to seek medical attention.

It is understood that the State Food and Drug Administration (SFDA) has asked Sapolex to start clinical effectiveness trials as soon as possible and report the evaluation results to SFDA within three years.

It remains to be seen what the results of the multi-center Phase III clinical trial data on Saproxel will be!

As a pharma.com that has been complained about by Saphris for publishing an article that scientifically describes Saphris eye drops, we're here to answer that question:

Recently, on the "miracle drug" Sapocephalus treatment of senile cataract efficacy, the media made a lot of noise, Sapocephalus in the end can not treat cataracts?

Age-related cataracts, medically called age-related cataracts, are caused by clouding of the lens in middle-aged and elderly people. Its occurrence is related to ultraviolet radiation, alcoholism, smoking, women having more children, cardiovascular disease, drugs, and trauma to the body. Cataracts can be divided into four stages according to the course of the disease, namely, incipient, expansion, maturation, and over-maturation. According to the pathogenesis of cataract treatment drugs are categorized as follows:

1. Antioxidant damage drugs: glutathione eye drops, taurine eye drops

2. Antiquinone drugs: Pinoxin sodium eye drops (Carlin-U, Intravitreal), Focalin eye drops

3. Aldose reductase inhibitors: Bendazac Lysine Eye Drops (Saproxil)

4. Adjuvant nutraceuticals: amiodarone eye drops

5. Proprietary Chinese medicines: cataract powder, musk pearl eye drops

After checking the instructions of the drugs, the instructions of Glutathione Eye Drops, Pinoxin Sodium Eye Drops, Focalin Eye Drops, Bendazac Lysine Eye Drops, and Amiodarone Peptide Eye Drops stated the indications as: early or early stage of senile cataracts; the indications of Obturatorium Eye Drops: senile cataracts; the indications of Musk Pearl Mingsume Eye Drops: senile cataracts at the beginning and middle stages; the indications of Taurine Eye Drops are the metabolic dysfunction of Taurine caused by the Taurine eye drops are indicated for cataracts caused by metabolic disorders of taurine.

It is currently believed that these medications may prevent or delay the onset and progression of senile cataracts at an early stage, and an ideal medication has not yet been found to normalize lens metabolism and cause the clouding to disappear. Neither can Saproxil! Surgery can be considered when cataracts interfere with work and life. Removal of the clouded lens is the best treatment for cataracts.

Author(s): Meixin Liu, Ruijun Yuan, Tianjin Ophthalmology Hospital; Member of Pharmacovigilance.com

The authoritative interpretation of Pharmaceutical Affairs, unauthorized reproduction, plagiarism will be punished.

Can Saphris eye drops treat cataracts? This may just be wishful thinking.

According to Saproxel, 0.5% Bendazac Lysine Eye Drops are effective and efficacious in slowing the progression of senile cataracts and improving or maintaining vision; it is a safe and effective anti-cataract drug. However, this claim has been challenged.

Recently, the question about the efficacy of Saproxis eye drops continued in the community, many media competing reports heat, patients are not unable to judge, for patients who do not want to do surgery, to buy, to use, however, the State Food and Drug Administration could not help but sit down and took the initiative to intervene in.

On the evening of December 6, the State Food and Drug Administration issued a notice stating that, in view of the fact that some doctors in the medical profession have questioned the efficacy of Bendazac Lysine Eye Drops (trade name: Saproxis) produced by Zhejiang Saproxis Pharmaceuticals Co, Ltd, the Zhejiang Food and Drug Administration is requested to, in accordance with the "Drug Administration Law of the People's Republic of China" and the relevant provisions on the consistency of evaluation of the quality and efficacy of generic medicines, urge the enterprise to In accordance with the Drug Administration Law of the People's Republic of China and the relevant provisions of the consistency evaluation of quality and efficacy of generic drugs, Zhejiang Food and Drug Administration should supervise the enterprise to start the clinical efficacy test as soon as possible, and report the evaluation results to the Drug Evaluation Center of the State Food and Drug Administration within three years.

In the short term, the above notice may bring important impact to the sales of Saproxil drops, and it is disclosed that, for Saproxil drops, eye drops that is its main reliance on the product, and now is required to start clinical effectiveness trials as soon as possible, which will be a sharp decline in the market's sense of trust, the patient's willingness to decline in purchasing power.

Of course, cataract, as one of the diseases that plague the health of the eyes, we can not wrongly accuse every attempt to improve the recovery of the behavior and subject, looking forward to scientific, fair and objective evaluation results as soon as possible.

For this eye drop incident, as a doctor is very helpless, I hope that through their limited power, to bring the correct knowledge, do not delay the condition of everyone.

In every group class, I almost always encountered this problem, and every time my answer was also to advise people not to use it. But the power of an individual is really limited, even if 500 people listen to the class each time, compared to our hundreds of thousands of cataract patients, this number is too insignificant.

Now, the advice to all of you who have this type of condition is to get it reviewed and operated on if you should. Don't delay any longer!

Do you understand if I express it this way?

Sapphire's TV commercials can all be broadcast to make you dizzy and call you tasteless for dinner ...... Just ask, are all TV commercials free? In the end, who pays the bill? Consumers! All of the overwhelming advertising products are paid for by consumers. You research to see, advertising more products, the old expensive!

The cataract business logic of Saproxel is strong instead of falling in the negative.

Recently Saproxis was openly questioned by the medical media, an article "a year wildly sold 750 million brainwashing drug, please spare the elderly in China" detonated in the circle of friends, the spearhead pointed directly at the Saproxis eye drops.

The article quoted several ophthalmologists and authoritative literature to prove that "Saproxil Eye Drops" for the prevention and treatment of cataracts is a big lie; it is a brainwashing advertisement and marketing campaign to "victimize" the elderly, causing them to delay treatment and put them at risk of losing their eyesight.

The article also said that "ophthalmologists often joke that if anyone can develop drugs to treat cataracts, it's no problem to get a Nobel Prize." Visible cataracts want to cut through the bottom of the drug treatment of the difficulty is very huge, but also from the side of the cataracts of the universality of the article also said, as long as the long enough to live, will be in the life of a cataract at some point in time.

When it comes to advertising false propaganda, it has to be said that, knowing that cataracts are hard to see, why did the advertisements type in such small print, and why do they have to be pompous if they don't have ulterior motives? However, Saprox is not only doing this in this advertisement, most of the advertisements have the same tactics. Not only does Saprox advertise that it can prevent and treat cataracts, but it also lists the symptoms of cataracts. This is the smartest part of the ad: replacing the disease with a symptom.

The company then responded with a query, but the response was too blank. Announcement is even more interesting. Words "have a certain effect", "efficacy is accurate", so whether a little bit of their own products are not quite sure, with the efficacy of the exact but do not use the efficacy of the significant, efficacy of the exact meaning should be just Sharp Ace is used for cataracts of the drug, right.

Huge market potential, marketing "stepping on the spot"

From the sales volume and product occupancy can be seen in the market share of Sapoce is quite large, and is not comparable to other brands, the industry leading position is self-evident. Saproxis eye drops not only sell the best, or the most expensive, visible in the market recognition is very high, there are two main reasons:

One is to take the lead in the treatment of cataract drug market gaps in the layout, and now appeared competitive products advantages are not obvious.

Secondly, advertising and marketing, with the overwhelming advertising campaign, when it comes to the brand image of Saproxel, every Cantonese can recall the familiar faces of "Uncle Kang" and "Auntie Kang", and "Foreign Daughter-in-Law, Local Lang" is a serial drama that has not come to an end, and it has left a deep impression on people. When cable TV was not yet popular, it was a TV series that every household had watched, so it left a very deep impression and the brand effect was highlighted.

As it happens, the number of patients suffering from cataracts is increasing in the face of aging, and it is also true that if you live long enough, you will run into cataracts at some point in your life. Even though there is a global consensus that no oral medication or eye drops can effectively treat cataracts, and the only way to recover is through surgical treatment, it is important to realize that older people are afraid of going under the knife, so why would they want to go to surgery for something that can be done with medication and water? Therefore, the emergence of the hot Saproxel has become their best choice, and the chosen Auntie Combercorn is precisely the most familiar to the middle-aged and the elderly, the representative of health and happiness, so this is undoubtedly the best choice.

As a result, many young people will buy Saphris eye drops for their parents to save the ever-blurring vision of the elderly. The large elderly population and high incidence, Saprox provides a broad market space, sales can rise 41 times in 9 years , just 9 years, relying on the advertising frenzy in the prime time, the annual sales of this eye drops soared from 670,000 in 2008 to 28 million in 2016, and close to 300 million dollars a year in advertising can be said to have spent its place. Saproxil eye drops contributed $754 million in revenue to the company last year, with a gross profit of $713 million.

Profiteering Behind the Earnings Report

Looking through its A-share annual report.

Eye drops mainly refers to Saproxis cataract eye drops, and Cefixime granules are mainly used for: acute purulent cholangitis, Klebsiella pneumonia, bronchitis, acute cholangitis, gonorrheal urethritis, coccidioidomycosis pneumonia, pneumonia acute bronchial. And Saproxis can only be considered to be in the front of this market share, and is not a leading company. So the main performance support is still Saproxis Cataract Eye Drops.

Sharp Ace's eye drops contributed 754 million revenue to the company in 2016, accounting for 77.03% of the total revenue, and this small eye drops surprisingly have a gross margin of 95%, no wonder it is so straightforward to call it Sharp Ace, an eye drop product to support into the market value of 6 billion. Visible Sharp Ace in the industry's position is so unshakeable, but also shows the cataract treatment drugs market demand potential.

Big negative, stock price firms up

As the main products to survive problems, it will be a devastating impact, as a listed company, no doubt the market feedback will be the most intuitive.

The stock market in Monday's bidding opening once sealed a stop, but then the stock began to rebound quickly, down only 1.77%, so strong rebound, let a person a little bit unable to feel the head difficult, December 5 after a low opening shock, the end of the disk once again a strong rebound, the final close of 22.89 yuan per share, Sharp Ace performance is far more than the current market other small and medium-sized board shares to be strong, visible stocks affected by the bearish news is not big, but rather than the current market sentiment of the other appears to be more strong.

There are three reasons for this:

① First, the market to take over the plate is larger. Can see the disk, Monday appeared since the company listed since the day's largest trading volume of 216 million, but even such a large sell-off is difficult to create too much noise, obviously take over the funds are prepared to make Sharp Ace in the so negative news after the final only closed down 3.33%. On Tuesday, the SSE was depressed and small and medium-sized creators have a large divergence, Sapphire even if the plate was down 3%, the end of the day is also a strong pull-up. Visible willingness to undertake the funds with a strong purpose.

② Chips are concentrated in the hands of a few people. From the point of view of the outstanding shareholders, the second quarter of 2017 compared to the first quarter of the number of shareholders holding a large change, and this phenomenon also continued into the third quarter, and the degree of concentration is more centralized, can be guessed is that there are capital groups in the gradual increase in the holdings of Sharp Acceptance, this can all be manifested from the data.

The circulation ratio is extremely small, most of them are in the hands of the company's shareholders, there are 34.39% restricted circulation of shares. And the ten largest shareholders have 4 trust, I believe that these trust in the absence of certain negative news is not easy to carry out changes, and the fund's holdings of the poor, in front of such a large acceptance of the disk is estimated to be all thrown out of the manufacture of not too much impact.

Such a large amount of funds to take over, does this mean that the stock price will not fall ah? Is it possible to boldly buy Sharp Acres, can only say that the current situation can only say that the big undertaking disk, just the market reflected with a purpose, does not mean that the market will always be at a certain time surge of funds to undertake.

Saphris eye drops are the main product of Saphris. If the next problem escalates, the medical media once again against Sharp Acres to make in-depth questioning, justified proof of the actual efficacy of the actual role of the drug does not have the actual role of the Food and Drug Administration identified Sharp Acres as a substandard drug, Sharp Acres is difficult to validate the product with the evidence, then the next risk is self-evident, I'm afraid that Sharp Acres may not necessarily be able to fight back. May face the risk of product suspension self-test and so on. So from the investment point of view, the investment is to avoid reducing the risk of obtaining returns, in front of the risk of investment can be seen, choose to take the risk is a little bit with the original intention of the investment departed from the flavor of gambling instead of a little bit stronger, the gentleman does not stand under a dangerous wall.

③ Too little attention

One is that the mainstream media pay too little attention to the questioned events, and the lack of hotspot effect can be seen from the statistics out of the big data. The second is that the incident is only questioned, not more powerful verification. So the results of the market performance is also reasonable.

Why is such a controversial drug on the market?

First of all, cataract treatment can only be solved by surgery, the market temporarily does not have any kind of drug can cure cataract, as an innovative drug is undoubtedly should be given support, at the same time, the long-term lack of cataract treatment drugs, then this 0.5% Bendazac Lysine Eye Drops to slow down the development of senile cataracts and improve or maintain visual acuity has a certain role in the drug is undoubtedly to fill the gap in the best choice, while the Give more support to these innovative companies, and naturally they can go to market naturally.

Secondly, Saproxil was approved for marketing in the 1990s, when China's approval standards and the level of scrutiny by the drug regulatory authorities were not very strict or relatively backward in terms of the level of medical care, and support was given to companies that were brave enough to innovate, whereas today's regulatory wholesalers are far more rigorous than they were at the end of the 1990s.

Does it mean that companies like Saproxel should be characterized no future development space, in fact, this kind of news is actually more common in the country, such as Dong'a Ajiao pigs and cattle instead of donkeys to produce gum, Sunflower Pharmaceuticals use low-quality traditional Chinese medicine tablets, Tongrentang cinnabar exceeded the standard and so on the incident, in fact, the problem is mainly in the control for the Pharmacy and Pharmacy Administration is negligence, resulting in the problem of the long-term existence of the problem, but also boosted the enterprise to the Drug manufacturing rigor. So the problem is still to be solved at the root.

The company's core product is the treatment of early senile cataract Saproxis eye drops, the company for the domestic cataract patients to seek medical treatment rate is low, the development of the cataract drug market is immature status quo, give full play to the technology of Saproxis eye drops first, although said at this stage was challenged by the false propaganda, the eye drops for the treatment of cataracts and the role of the recovery of basically no return to heaven, but still have an important role in slowing down the development of cataracts, the market competition is too powerful to be ignored to continue to expand the market share after the recovery. Competition in the market is too small to ignore the continued expansion of market share after recovery. Increased investment in research and development of the entire cataract drug chain.

And now Sharp Acceptance should come up with more powerful evidence to prove the effectiveness of the drug back to questioning, in for many ophthalmologists to Sharp Acceptance to do a strong clinical trials, I think this is an effective way to restore market confidence, the company's senior management will also consider the feasibility, but this requires a long process.

If the market questioning is further escalated, and it is determined that the advertisement of Saphris is exaggerated, the actual efficacy of the drug has no real effect, and the Food and Drug Administration determines that Saphris is an unqualified drug, then the next risk is self-evident. As the main product of survival if such a problem occurs, in the end it can only be said that the success of the eye drops, but also the defeat of the eye drops. The latest news is that the Zhejiang Food and Drug Inspection Bureau investigation did not find Saproxis sampling test failed.